Heart transplant rejection pathology

Abstract

Baclgrpund/Aim. Heart transplantation is the most effective way to treat patients in the terminal stage of heart failure. Endomyocardial biopsy has proven to be a safe and appropriate technique, with little sampling error and remains to this day one of the most commonly used methods for diagnosing of acute rejection. In 1990, ISHLT defined a standardized system for grading the severity of acute transplant rejection regarding endomyocardial sampling histopathological analysis. The aim of study is assessment of morphological, immunohistochemical and immunofluorescent markers of cellular and antibody-mediated rejection of heart transplant in patients monitored during 2020. Methods. From 31 patients transplanted at the Clinic for Cardiac Surgery of the Clinical Center of Serbia, endomyocardial biopsy material was obtained, then processed and analyzed at the Institute of Pathology of the Medical Faculty, University of Belgrade. Results. The average Transplant Rejection Score (TRS) value was 0.42. Spearman 's correlation test didn?t show a statistically significant relationship between the TRS score value and the difference between the ejection fraction values three and twelve months after transplantation. Conclusion. The mean TRS score value obtained in this study suggests dominant cell graft rejection.

Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Immunocompromised and Immune Reconstituted CAnN.Cg-Foxn1nu/Crl Nude Mice

“…Given our in vivo tumor assessment results when considered in totality with ex vivo histopathology and immunohistochemistry results, we hypothesize the results observed in immune reconstituted mice, independent of treatment, are indicative of host, innate immune system rejection of the human PDAC xenograft employed in our study. Our results demonstrate the temporal relationship between CD-3 + T-cell transfer to start of tumor volume regression, rapid rate of tumor volume regression and pathology results, collectively support host immune-mediated rejection of the xenograft as our results are consistent with host immune system-mediated transplant rejection as reported by many investigators [111][112][113][114][115]. Results demonstrating TPV/eGFP treatment was most similar to vehicle treated, immune reconstituted animals as compared to the CCL-2 and IL-2 variants, with the thymidine kinase (TPV gene 66R) knockout, is likely a result of maintained TPV/eGFP variant thymidine kinase gene activity.…”